
Roche

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1 pricing and product initiatives of competitors;
2 legislative and regulatory developments and economic conditions;
3 delay or inability in obtaining regulatory approvals or bringing products to market;
4 fluctuations in currency exchange rates and general financial market conditions;
5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6 increased government pricing pressures;
7 interruptions in production;
8 loss of or inability to obtain adequate protection for intellectual property rights;
9 litigation;
10 loss of key executives or other employees; and
11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com

Roche

Q1 2022 Sales

Basel, 25 April 2022

Group

Severin Schwan
Chief Executive Officer

Q1 2022 performance

Outlook

Q1 2022: Strong performance for Pharma and Diagnostics

Strong Group sales +11% driven by both divisions

- Pharma performing well (+6%) and delivering on current products and new launches
- Diagnostics maintaining growth momentum (+24%) including strong base business growth (+10%)

Portfolio rejuvenation ongoing with successful launches and Diagnostics increasing installed base

- Pharma with successful launch of Vabysmo and Susvimo in ophthalmology; upcoming launches for Polivy in 1L DLBCL & CD20xCD3 bi-specifics in hematology
- Diagnostics received EUA for the SARS-CoV-2 rapid antigen test; significant increase of installed base in molecular diagnostics contributing to strong base business growth; molecular testing solutions launched to track SARS-CoV-2 Omicron variants

Innovative late-stage pipeline with strong potential for future growth & significant news flow ahead

- Pharma: Read-outs in oncology for Tecentriq in four adjuvant indications, tiragolumab + Tecentriq combination in various indications and gantenerumab in Alzheimer's disease
- Diagnostics: BenchMark ULTRA PLUS, Digital Pathology Slide Scanner, Digital LightCycler, Elecsys pTau/AB42 ratio Gen2 CSF (FDA)

Growth rates at CER (Constant exchange Rates)

Q1 2022: Group sales growth driven by strong performance in both divisions

	2022 CHFbn	2021 CHFbn	Change in % CHF	Change in % CER
Pharmaceuticals Division	**11.2**	10.6	**5**	**6**
Diagnostics Division	**5.3**	4.3	**22**	**24**
Roche Group	**16.4**	14.9	**10**	**11**

CER=Constant Exchange Rates; totals may include differences due to rounding

Q1 2022: Group sales +11% driven by both divisions



Growth rates at CER (Constant exchange Rates); * Q2 2020 sales severely impacted by COVID-19 pandemic onset ; [1]AHR: Avastin, Herceptin, Rituxan/MabThera

Q1 2022: Strong underlying business momentum



Diversification of Roche business



Q1 2022 values in reported CHFm, variances in CERm; [1] AHR: Avastin, Herceptin, Rituxan/MabThera sales erosion (2.5bn for FY 2022)

Q1 2022 performance

Outlook

2022 sales outlook confirmed

Sales drivers[1]

Pharma: New products with accelerating growth

Diagnostics: Base business with strong growth

AHR[2] biosimilars: Roughly CHF -2.5 bn sales erosion

COVID-19 sales for Diagnostics and Pharma around CHF 5 bn

- **Guidance stable to low-single digit group sales growth**
- **Group sales to grow high-single digit if COVID-19 sales and AHR get excluded**
- **Guidance based on a scenario where the Delta/Omicron variants represent the last major wave**

[1] At Constant Exchange Rates (CER); [2] AHR=Avastin, Herceptin, Rituxan/MabThera

2022: Upcoming newsflow

Pharma

Ongoing and upcoming launches

- **Vabysmo** in DME/nAMD
- **Susvimo** in nAMD
- **Polivy** in 1L DLBCL
- **mosunetuzumab** in FL
- **glofitamab** in DLBCL

Late stage pipeline

- **3 tiragolumab + Tecentriq studies** NSCLC, Cervical, Esophageal
- **4 Tecentriq adjuvant studies** Head & Neck, Renal, HCC, neoadjuvant NSCLC
- **gantenerumab** in Alzheimer's disease

Diagnostics

Upcoming launches

BenchMark ULTRA PLUS	Automated immunohistochemistry/in situ hybridization advanced staining platform
DP600	High capacity pathology slide scanner for high volume digitization applications
Digital LightCycler	Novel digital PCR platform
Elecsys pTau/AB42 ratio Gen2 CSF (FDA)	Detect amyloid disease & enable a broader availability of testing for Alzheimer's Disease

Neuroscience
Oncology
Ophthalmology
Diagnostics

DME=diabetic macular edema; nAMD=neovascular age-related macular degeneration; DLBCL=diffuse large B-cell lymphoma; FL=follicular lymphoma; NSCLC=non-small cell lung cancer; HCC=hepatocellular carcinoma; CSF=cerebrospinal fluid; PCR=polymerase chain reaction

First Roche ESG event focusing on access to healthcare

Roche ESG Event on May 16
Access to Healthcare

15:00 - 16:30 CEST / 14:00 – 15:30 BST
09:00 – 10:30 am EDT / 6:00 – 7:30 am PDT

Our 10-year ambitions to be achieved by 2030

Pharmaceuticals: Double medical advances at less costs to society

Diagnostics: Double patient access to novel, high-medical-value diagnostics solutions

2022 outlook

Group sales growth[1]	• Stable to low-single digit
Core EPS growth[1]	• Low- to mid-single digit (including accretion of 4.4%p from share repurchase)
Dividend outlook	• Further increase dividend in Swiss francs

[1] At Constant Exchange Rates (CER)

Pharmaceuticals Division

Bill Anderson
CEO Roche Pharmaceuticals

Q1 2022: Pharmaceuticals Division sales

Good growth momentum

	2022 CHFm	2021 CHFm	Change in % CHF	Change in % CER
Pharmaceuticals Division	**11,159**	**10,600**	**5**	**6**
United States	5,489	5,292	4	2
Europe	2,072	2,175	-5	-1
Japan	1,337	852	57	69
International	2,261	2,281	-1	0

CER=Constant Exchange Rates

Q1 2022: Continued Pharma portfolio rejuvenation



Absolute values and growth rates at Constant Exchange Rates (CER)

Q1 2022: Oncology portfolio rejuvenation progressing well



HER2 franchise

- Kadcyla (+9%) with growth ex-US due to adjuvant BC
- Perjeta (+1%) growth cannibalized by successful Phesgo launch
- Phesgo (CHF 146m): Conversion and geographic expansion ongoing

Tecentriq

- Growth (+8%) driven by adjuvant NSCLC, 1L HCC and 1L SCLC

Avastin franchise

- Biosimilar erosion in all regions

Hematology franchise

- Venclexta*: Growth driven by 1L AML and 1L and R/R CLL
- Gazyva (+7%): Growth due to 1L FL and in 1L CLL
- Polivy (+89%): Growth acceleration in Q1 partly due to R/R DLBCL; Positive CHMP opinion in 1L DLBCL (POLARIX)
- Mosunetuzumab: Positive CHMP opinion in 3L+ FL

Alecensa

- Growth (+23%) driven by all regions, especially International and US

CER=Constant Exchange Rates; Q1 2022 Oncology sales: CHF 4.9bn; CER growth -3%; * Venclexta sales booked by AbbVie and therefore not included (FY-2021 sales of USD 1.820bn, +36% YoY reported); Polivy in collaboration with Seagen; BC=breast cancer; HCC=hepatocellular carcinoma; SCLC=small cell lung cancer; NSCLC=non-small cell lung cancer; AML=acute myeloid leukemia; R/R CLL=relapsed/refractory chronic lymphocytic leukemia; FL=follicular lymphoma; DLBCL=diffuse large B cell lymphoma; CHMP=Committee for Medicinal Products for Human Use

HER2 franchise: Phesgo with strong global launch

Perjeta conversion rate approaching 25% in early launch countries

PHESGO® PERTUZUMAB-TRASTUZUMAB

Roche

Phesgo cutting administration time & costs



Global Perjeta conversion rate**



- Phesgo administration results in significantly reduced healthcare costs and resource use
- First approved by FDA and EMA in 2020

P=Perjeta; H=Herceptin; SC=subcutaneous; IV=intravenous; *Ranges driven by differences in loading and maintenance dose; **Perjeta conversion rate is based on volumes (vials) and includes all launch countries after the 2nd quarter after the launch (17 countries); Phesgo in collaboration with Halozyme

Tecentriq overview: Adjuvant program to read out in 2022



Tecentriq Q1 update

- US: Sales still impacted by label changes
- Japan: Sales impacted by mandatory price cut

Lung franchise (NSCLC, SCLC)

- EU: Growth driven by 1L SCLC; Positive CHMP opinion in adjuvant PDL1+ NSCLC
- US: Strong launch in adjuvant PDL1+ NSCLC

GI franchise (HCC)

- US/EU/Japan: Growth driven by 1L HCC

Outlook 2022

- Further growth due to first-to-market indications adjuvant PDL1+ NSCLC and 1L HCC
- 4 Ph III Tecentriq adjuvant studies and 3 Ph II/III tiragolumab + Tecentriq studies reading out

CER=Constant Exchange Rates; NSCLC=non small cell lung cancer; SCLC=small cell lung cancer; HCC=hepatocellular cancer; CHMP=Committee for Medicinal Products for Human Use

Hemophilia A franchise: Hemlibra accepted as new standard of care

34% US/EU-5 patient share reached



Hemophilia Q1 update

- Nearly 17,000 patients currently treated globally
- Hemlibra continues to penetrate across all approved patient types
- EU: Non-inhibitors market shares of >50% in the UK and >40% in France achieved

Outlook 2022

- US/EU: Further patient share gains in non-inhibitors
- EU: Label expansion to include mild/moderate patients (HAVEN 6) expected

CER=Constant Exchange Rates

Immunology franchise: Still moved by COVID-19



Immunology Q1 update

Actemra (+3%)

- Remains leading RA monotherapy in EU-5
- Shift from IV to SC continues with SC sales accounting for >50%
- Around 50% of IV sales expected to be due to COVID-19

Xolair (+9%)

- Remains the leader in biologics asthma market; Continued growth in CSU

Outlook 2022

- Actemra: COVID-19 sales expected to decline with lower hospitalization rates

CER=Constant Exchange Rates; RA=rheumatoid arthritis; IV=intravenous; SC=subcutaneous; CSU=chronic spontaneous urticaria

MS franchise: Ocrevus global market share reaches 20%



Q1 update

- US/EU still impacted by COVID-19
- Mitigation plans for late stage MS development programs initiated due to situation in Ukraine/Russia
- Ph III (OCARINA II) for Ocrevus 6-month SC dosing initiated

Outlook 2022

- Further market share gains expected

CER=Constant Exchange Rates; MS=multiple sclerosis; SC=subcutaneous

SMA franchise: Evrysdi with strong US and EU launches

Most prescribed treatment in the US with >20% share; Germany with >30% share



Q1 update

- ~5,000 patients treated world wide (commercial, clinical trials, compassionate use)
- US: Growth driven by switch and naive patient starts
- EU: Strong launches in early launch countries
- Ph II/III (MANATEE) Evrysdi + anti-myostatin combination study initiated

Outlook 2022

- Continued growth and market share gains expected
- US/EU: Label extension (<2 months old) based on Ph II RAINBOWFISH expected (priority review)

CER=Constant Exchange Rates; SMA=spinal muscular atrophy; Anti-myostatin (GYM329) in collaboration with Chugai

SMA franchise: New data in presymptomatic SMA

Indication extension for <2 months of age filed with FDA and EMA

Ph II (RAINBOWFISH): 1 year interim results in infants (<2 months of age)



4 infants with 2 SMN2 copies:

- Most infants treated for >12 months achieved near-maximum CHOP-INTEND scores
- Most infants achieved motor milestones within WHO windows for healthy children





3 infants with >2 SMN2 copies:

- All infants treated for >12 months achieved the maximum CHOP-INTEND score
- Most infants achieved motor milestones within WHO windows for healthy children



Finkel et al., MDA conference 2022 (abstract 76); SMA=spinal muscular atrophy; WHO=World Health Organisation; CHOP-INTEND=The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders; In collaboration with the SMA foundation and PTC Therapeutics

Ophthalmology franchise: Follow-up data for Vabysmo in DME

Proportion of patients achieving Q16W dosing increases to ≥ 60% at week 96

Angiogenesis, Exudation, Degeneration 2022 February 12

Ph III (YOSEMITE, RHINE) in DME: Dosing intervals of patients at year 1 and 2



- Anti-VEGF/Ang2 bispecific mAb with new dual mechanism of action to promote vascular stability
- Proportion of patients achieving Q16W dosing increased from >50% at week 52 to ≥ 60% at week 96; 1-year BCVA gains and improved anatomic outcomes (including CST) were maintained through year 2
- 2-year data in nAMD to be presented at upcoming conference

Wells J.A. et al., Angiogenesis conference 2022; DME=diabetic macular edema; CST=central subfield thickness; nAMD=neovascular age-related macular degeneration; mAb=monoclonal Antibody

Ophthalmology franchise: Follow-up data for Susvimo in nAMD

Vision and anatomical outcomes maintained through year 2

Angiogenesis, Exudation, Degeneration 2022 February 12

Ph III (ARCHWAY) in nAMD: 2-year results for Susvimo Q24W dosing

BCVA change from baseline



CPT change from baseline



- First eye implant with continuous drug delivery offering 6-month dosing alternative to frequent eye injections
- Long-term vision and anatomic results through year 2 were comparable with monthly ranibizumab injections; safety profile well characterized and manageable
- Ph III (PAGODA, PAVILION) results in DME/DR expected in late 2022, Ph III (VELODROME) testing Q9M dosing on-going

Wykoff C.C. et al., Angiogenesis conference 2022; nAMD=neovascular age-related macular degeneration; BCVA=best-corrected visual acuity; CPT=center point thickness (measured ILM-RPE); PDS=Port Delivery System with ranibizumab (Susvimo); DME=diabetic macular edema; DR=diabetic retinopathy; Q24W=every 24 weeks; Q9M=every 9 months

2022: Key late-stage newsflow* and upcoming IR events

	Compound	Indication	Milestone	
Regulatory	**Vabysmo**	nAMD/DME	US/EU approval	US ✓
	Susvimo	nAMD	EU approval	
	mosunetuzumab	3L+ FL	US/EU approval	
	Tecentriq	Adjuvant NSCLC	EU approval	
	Hemlibra	Mild to moderate hemophilia A	EU approval	
	Polivy + R-CHP	1L DLBCL	EU/US approval	
Phase III / pivotal readouts	**glofitamab**	3L+ DLBCL	Ph Ib NP30179	✓
	Tecentriq + tiragolumab + chemo	1L ES-SCLC	Ph III SKYSCRAPER-02	✗
	Tecentriq + chemo	Adjuvant SCCHN	Ph III IMvoke010	
	Tecentriq + tiragolumab	1L PDL1+ NSCLC	Ph III SKYSCRAPER-01	
	Tecentriq	Adjuvant RCC	Ph III IMmotion010	
	giredestrant	2/3L HR+ mBC	Ph II acelERA	✗
	Tecentriq + chemo	Adjuvant HCC	Ph III IMbrave050	
	Venclexta + dexamethasone	t(11;14) MM	Ph III CANOVA	
	Tecentriq + chemo	Neoadjuvant NSCLC	Ph III IMpower030	
	Tecentriq + tiragolumab + chemo	1L esophageal cancer	Ph III SKYSCRAPER-08	
	Alecensa	Adjuvant ALK+ NSCLC	Ph III ALINA	2023
	gantenerumab	Alzheimer's disease	Ph III GRADUATE 1/2	
	Susvimo	DME	Ph III PAGODA	
	Susvimo	DR	Ph III PAVILION	

Virtual event Angiogenesis ✓	***Virtual event MDA*** ✓	***Roche ESG Day Access to Healthcare***	***Virtual event ASCO***	***Roche Pharma Day***
Monday, 14 February 16:30 to 17:45 CEST	***Wednesday, 16 March 16:30 to 17:30 CEST***	***Monday, 16 May 15:00 to 16:30 CEST***	***Monday, 6 June 16:00 to 17:30 CEST***	***Monday, 12 September TBC***

* Outcome studies are event-driven: timelines may change

Diagnostics Division

Thomas Schinecker
CEO Roche Diagnostics

Q1 2022: Diagnostics Division sales

Sales increase of +24% driven by COVID-19 testing and base business

	2022 CHFm	2021 CHFm	Change in % CHF	Change in % CER
Diagnostics Division	**5,286**	**4,330**	**22**	**24**
Core Lab[1]	1,896	1,786	6	8
Point of Care[1]	1,466	806	82	84
Molecular Lab[1]	1,189	996	19	21
Diabetes Care	417	460	-9	-7
Pathology Lab	318	282	13	14

CER=Constant Exchange Rates; underlying growth of Core Lab excluding Roche Information Solutions: +8%; [1]Sales in the Point of Care customer area include sales from the Liat business (POC molecular), and sales in the Core Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC molecular sales = 90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21=194mCHF. In Q1 21 LS Alliances = 21mCHF, Q2 21=23mCHF, Q3 21=23mCHF, Q4 21=20mCHF.

Q1 2022: Diagnostics Division regional sales

Very strong growth in all regions; rapid antigen test sales contributing to US growth



Growth rates at CER (Constant exchange Rates); [1] Europe, Middle East and Africa

Q1 2022: Diagnostics Division highlights

Strong growth despite a high base in Q1 2021



- Immunodiagnostics (+11%)
- Clinical Chemistry (+8%)

- POC Immunodiagnostics (+107%)
- POC Molecular[3] (+83%)

- Virology (+31%)

- Blood glucose monitoring (-8%)
- Insulin delivery systems (+11%)

- Advanced staining (+14%)
- Companion diagnostics (+19%)

CER=Constant Exchange Rates; POC=point of care; [1] Underlying growth of Core Lab excluding Roche Information Solutions: +8%; [2] EMEA=Europe, Middle East and Africa; [3] Sales in the Point of Care customer area include sales from the Liat business (POC molecular), and sales in the Core Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC molecular sales = 90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21=194mCHF. In Q1 21 LS Alliances = 21mCHF, Q2 21=23mCHF, Q3 21=23mCHF, Q4 21=20mCHF.

Diagnostics Division sales growth by quarter

Very strong COVID-19 and base business growth



COVID-19 sales	Q1: 0.1bn	Q2: 0.6bn	Q3: 0.6bn	Q4: 1.1bn	Q1: 1.2bn	Q2: 1.3bn	Q3: 1bn	Q4: 1.2bn	Q1: 1.9bn

Growth rates at CER (Constant exchange Rates); [1] Quarterly sales growth excluding COVID-19 sales

cobas® 5800/6800/8800 molecular menu expansion driving growth

Further growing the installed base in 2022

Donor Screening	Blood Borne Disease	Sexual Health	Transplant	Respiratory	Antimicrobial Stewardship
MPX ✓	HIV-1 ✓	HPV ✓	CMV ✓	Flu A/B & RSV (OMNI) ✓	MTB-RIF/INH ✓
WNV ✓	HBV ✓	CT/NG ✓	EBV ✓	MTB ✓	C.diff ✓
DPX ✓	HCV ✓	TV/MG ✓	BKV ✓	MAI ✓	
HEV ✓	HIV-1/2 Qual ✓	PivNG ✓	ADV Quant	SARS-CoV-2 ✓	
CHIKV/DENV ✓	HSV-1/2/VZV (OMNI) ✓	HPV Self-sampling	HSV-1/2/VZV	SARS-CoV-2 & Flu A/B ✓	
Zika ✓	HBV RNA (IA) ✓	BV/CV		SARS-CoV-2 Variant ✓	
Malaria	HBV RNA	MG Resistance		Influenza A/B & RSV ✓	
		NG Resistance		AMER ✓	
				Parainfluenza 1-4 ✓	
				SARS CoV-2 DUO	
				MPLX Respiratory	

Launched in 2021

In development

>1,900 cobas® 6800/8800 installed base

>500 cobas® 5800 placements expected in 2022

MPX=multiplex detection of HIV-1, HIV-2, HCV=Hepatitis C and HBV=Hepatitis B ; WNV=West Nile virus; DPX=duplex detection of parvovirus B19 and HAV; HEV=Hepatitis E virus; CHIKV=chikungunya virus; DENV=Dengue virus; CMV=Cytomegalovirus; MTB=Mycobacterium tuberculosis; MAI=Mycobacterium avium-intracellulare infection; RIF=rifampicin; INH=isoniazid (detection of RIF/INH resistance in MTB positive samples); TV=trichomonas vaginalis; MG=mycoplasma genitalium; EBV=Epstein-Barr virus post-transplant monitoring; BKV=BK virus post-transplant monitoring; ADV=Adenovirus post-transplant monitoring; HSV-1/2/VZV=multiplex detection of Herpes simplex virus 1 and 2 and Varicella-zoster virus; MPLX=detect and discriminate multiple (up to 14) pathogens associated with a clinical syndrome, including SARS-CoV-2; Malaria=mosquito-borne infectious disease; SARS-CoV-2=2019 novel coronavirus; HSV=Herpes Simplex Virus; VZV=Varicella-zoster virus, the cause of chickenpox and herpes zoster (also called shingles); PivNG=Neisseria Gonorrhoeae Piv Gene Target; ADV=Adenovirus; AMER= Adenovirus, metapneumovirus, enterovirus, rhinovirus; HBV RNA (IA) = HBV RNA Investigational Assay; HPV=Human papillomavirus; CT/NG=Chlamydia Trachomatis and Neisseria Gonorrhoeae; C.diff=Clostridioides difficile; RSV=Respiratory syncytial; Flu A/B=Influenza B

Upcoming launch of cobas® SARS-CoV-2 DUO

Providing accurate diagnosis of SARS-CoV-2 infection for proper patient management



E: envelope protein gene
M: membrane protein gene
N: nucleocapsid protein gene

Orf: open reading frame
S: spike protein gene

Polymerase
R reporter dye
Q quencher

- Provide qualitative result of SARS-CoV-2 detection combined with the viral load result traceable to the WHO international standard in IU/mL
- Supports scalable testing on the fully automated **cobas**® 5800/6800/8800 systems and their broad menu

TIB-Molbiol SARS-Cov-2 menu for tracking virus evolution

Detecting major variants in hours vs a week for sequencing



>10 tests to differentiate all relevant variants

Roche Serum Work Area menu expansion driving future growth

>240 assays running on >100k installed cobas® SWA instruments

Broad IM + CC assay menu



Launched in 2021 & upcoming launches in 2022

Immuno chemistry assays	
EBV EBNA IgG (CE)	IGRA SARS-CoV-2 (CE)
EBV VCA IgG (CE)	HCV Duo (CE)
EBV IgM (CE)	Anti-HBs II[4] (US)
Anti-p53 (CE)	Anti-HAV II[4] (CN)
GAAD (CE)	HBsAg Confirmatory (US)
NT-proBNP claim extension[3] (CE)	AFP-L3 (CE)
TnT–hs claim extension[3] (CE)	Vit D total III[4] (US, CN)
PCT CE claim extension[3] (CE)	Androstendione (CN)
Vit D total III[4] (CE)	Active B12 (US)
Anti-HBe (US)	FT4 IV[4] (CE, US)
HBsAg Confirmatory (CE)	TG II[4] (US)
Alzh CSF biomarkers (CE)	

Clinical chemistry assays	
Fentanyl[5] (CE, US)	ASTP2[4] (US)
sTfR Gen 2[4] (CE)	ALTP2[4] (US)
Sirolimus (CN)	Benz 2[4] (US)
CRP4 (CN)	A1MG Controls[5] (CE)
	sTfR Gen 2[4] (US, CN)
	free PHNY2 (CE)
	NH3L2 (CN)

On market (Launched in 2021)	In development (to be launched in 2022)

IM: Immunochemistry; CC: Clinical chemistry; [1] Not including confirmatory tests, stat tests and special assays in the allergy panel. Variants of the same assay (e.g. for HIV AG/Ab, different kit sizes) are counted once; [2] Core unit| ISE |c 702 | c 702 | e 801 | e 801; [3] Claim extension, [4] Product update; [5] Partner Channel

Alzheimer's disease IVD blood tests development

Enabling access to Alzheimer's disease modifying therapies



- pTau 181 and ApoE4 have been selected based on clinical performance and robustness
- Clinical study results leading to the biomarkers selection will be published at AAIC (July 31st-Aug 4th)
- These biomarkers are used in the SKYLINE study (gantenerumab in pre-symptomatic Alzheimer's disease)
- Planned clinical validation to support IVD registration in major markets
- Launch of the **Elecsys®** amyloid plasma panel is planned together with gantenerumab

[1] Illustrative scheme; [2] Mean of clinical performance data from retrospective cohorts measured with Elecsys Amyloid Plasma Panel; [3] Elecsys pTau / Amyloid Beta 42 ratio

Roche Analyst Event on Diagnostics Division at AACC 2022

Chicago, Palmer House hotel, July 26, 6-7:15pm CDT

AACC = Annual Scientific Meeting and Clinical Lab exposition

Key launches 2022

Area		Product	Description	Market
Instruments	Pathology Lab	BenchMark ULTRA PLUS	Automated immunohistochemistry/in situ hybridization (ISH) advanced staining platform with enhanced software capabilities, workflow and testing efficiency	US & CE
		DP600	High capacity pathology slide scanner for high volume digitization applications	WW
	Core Lab	cobas® pure integrated solutions	Serum work area analyzer for low-to-medium sized labs	US
	Molecular Lab	cobas® 5800	Real-time PCR molecular testing for low volume labs	US
		Digital LightCycler	Novel digital PCR platform for lab developed tests (LDTs) and in-vitro diagnostics labs	WW
Tests	Pathology Lab	HER2 Low Breast	Assay for diagnosis of HER2 low expression breast cancer	US
		PRAME	First immunohistochemistry assay for differential diagnosis of benign from malignant melanocytic lesions in skin cancer	US & CE
		HPV Self Sampling	Self sample collection device for patients at home to collect sample for cervical cancer testing	CE
	Core Lab	cobas® HCV Duo	Antigen/antibody combined assay for faster diagnosis of hepatitis C	CE
		Elecsys pTau/AB42 ratio Gen2 (CSF)	Detect amyloid disease and enable a broader availability of testing for patients suspected of Alzheimer's Disease	US
	Molecular Lab	cobas® SARS-CoV-2 DUO	Automated RT-PCR assay for use on the cobas® 6800/8800 systems	US[2] & OUS[1]
		cobas® 5800 Menu Expansion	Assays to test for SARS-CoV-2, chlamydia trachomatis (CT)/neisseria gonorrhoeae (NG) and cytomegalovirus (CMV)	US & CE
Digital Solutions	Lab Insights	Chronic Kidney Disease InSight	Digital solution (mobile app and dashboard) providing insights for chronic kidney disease patient management	CE
		Cervical Cancer Screening	Digital solution (mobile app and workflow) improving the management of screening programs for cervical cancer	CE
		cobas® infinity edge suite	Portfolio of digital products to support decentralization of testing and data, to launch commercially with an open ecosystem	CE
		Lab Insights Platform	Data integration platform for laboratory customers across disciplines	CE
	Diabetes Care	RocheDiabetes Care Platform Payer Dashboard	Population-level insights via dashboard for HCPs, Admins and Payers	OUS[3]
		mySugr Pump Control	Extended functionalities (e.g. temporary basal rate import from a connected insulin pump), expanded smartphone compatibility	OUS[3]

CE: European Conformity, US: FDA approval, WW: Worldwide including CE, US and China, OUS: Outside the US; PCR: Polymerase Chain Reaction; RT: Real Time; [1] Research Use Only; [2] EUA: Emergency Use Authorization; [3] Only selected countries

Finance

Alan Hippe
Chief Financial Officer

Q1 2022: Highlights

Sales

- Group sales growth of +11% due to strong performance in Pharmaceuticals and Diagnostics division
- Pharma delivering well across entire portfolio; Diagnostics continuing with strong results in double-digit range

Currency impact on sales

- Slightly negative currency impact mainly due to EUR and JPY, partially offset by USD

Share repurchase of Roche from Novartis

- CHF 19bn bridge loan largely refinanced and repaid
- Roche issued in total USD 11bn and CHF 3bn of bonds since December 2021 at an average initial yield of 1.56% for an average maturity of 8.8 years

Patent settlement*

- USD 775m (CHF 765m @CER) revenue recorded as 'Income from out-licensing agreements' as part of core net income
- This revenue is taxable at Chugai's tax rate and partly attributable to Chugai's non-controlling interests

Growth rates at CER (Constant exchange Rates); *Ultomiris patent settlement between Chugai and Alexion

Q1 2022: Group Sales

CER Group sales increase of +11% driven by Diagnostics Division & Chugai (Ronapreve)



Absolute values in CHFm at Constant Exchange Rates (avg full year 2021); [1] avg. full year 2021 to avg YTD March 2022 fx impact

Q1 2022: Strong underlying business momentum

2022 outlook on COVID-19 related sales (+5bn) and AHR erosion (-2.5bn) confirmed



Q1 2022 values in reported CHFm, variances in CERm; [1] AHR: Avastin, Herceptin, Rituxan/MabThera sales erosion (2.5bn for FY 2022)

Novartis share repurchase: CHF 19bn bridge loan largely refinanced and repaid



- Roche issued in total USD 11bn and CHF 3bn of bonds since December 2021 at an average initial yield of 1.56% for an average maturity of 8.8 years

Exchange rate impact on sales growth

Slightly negative impact mainly from EUR, JPY and TRY partially offset by USD



CER=Constant Exchange Rates (avg full year 2021)

2022 currency impact



Assuming the 31 March 2022 exchange rates remain stable until end of 2022,
2022 impact[1] is expected to be (%p):

	Q1	HY	Sep YTD	FY
Sales	-1	-2	-2	-2
Core operating profit		-2		-2 to -3
Core EPS		-2		-2 to -3

[1] On group growth rates

First Roche ESG event focusing on access to healthcare

Roche ESG Event on May 16
Access to Healthcare

15:00 - 16:30 CEST / 14:00 – 15:30 BST
09:00 – 10:30 am EDT / 6:00 – 7:30 am PDT

Our 10-year ambitions to be achieved by 2030

Pharmaceuticals: Double medical advances at less costs to society

Diagnostics: Double patient access to novel, high-medical-value diagnostics solutions

2022 outlook

Group sales growth[1]	• Stable to low-single digit
Core EPS growth[1]	• Low- to mid-single digit (including accretion of 4.4%p from share repurchase)
Dividend outlook	• Further increase dividend in Swiss francs

[1] At Constant Exchange Rates (CER)

Doing now what patients need next

Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development (pRED)

Genentech research and early development (gRED)

Spark

Pharma sales appendix

Diagnostics sales appendix

Foreign exchange rates information

Changes to the development pipeline

Q1 2022 update

New to phase I

6 NMEs:
RG6344 BRAF inhibitor (3) – solid tumors
RG6333 CD19xCD28 + glofitamab – r/r NHL
RG6163 NME – psychiatric disorders
RG6156 EGFRvIIIxCD3 – glioblastoma
RG6319 LepB inhibitor – complicated urinary tract infection
RG7880 efmarodocokin alfa – aGVHD (new lead indication)

New to phase II

1 NME:
RG6084 PDL1 LNA – HBV

2 AIs:
RG6107 crovalimab – sickle cell disease
RG6026 glofitamab + chemo – 1L ctDNA high risk DLBCL

New to phase III

New to registration

1 NME (EU):
RG6026 glofitamab – 3L+ DLBCL

1AI (EU):
RG6413+RG6412 Ronapreve – SARS-CoV-2 hospitalised

Removed from phase I

1 NME:
RG6115 TLR7 agonist (4) - hepatocellular carcinoma

1 AI:
RG7601 Venclexta + gilteritinib – r/r AML

Removed from phase II

2 NMEs:
RG7769 PD1xTIM3 – solid tumors
RG7880 efmarodocokin alfa – inflammatory bowel disease (continues in phase I in aGVHD)

Removed from phase III

1 AI:
RG6058 tiragolumab + Tecentriq – 1L SCLC

Approvals

Status as of April 25, 2022

Roche Group development pipeline

Phase I (49 NMEs + 11 AIs)

RG6007	HLA-A2-WT1 x CD3	AML
RG6026	glofitamab monotherapy & combos	heme tumors
RG6058	tiragolumab combos	heme & solid tumors
RG6076	CD19-4-1BBL	heme tumors
RG6129	HLA-A2-MAGE-A4 x CD3	solid tumors
RG6160	cevostamab (FcRH5 x CD3)	r/r MM
RG6171	giredestrant (SERD)	solid tumors
RG6114	inavolisib (mPI3K alpha inh)	solid tumors
RG6156	EGFRvIII x CD3	glioblastoma
RG6180	autogene cevumeran±T	solid tumors
RG6185	belvarafenib (pan-RAF inh)+Cotellic	solid tumors
RG6189	FAP-CD40	solid tumors
RG6194	runimotamab (HER2 x CD3)	BC
RG6234	-	multiple myeloma
RG6279	PD1-IL2v	solid tumors
RG6286	-	colorectal cancer
RG6290	MAGE-A4 ImmTAC	solid tumors
RG6292	CD25 MAb ± T	solid tumors
RG6323	IL15/IL15Ra-Fc	solid tumors
RG6330	KRAS G12C	solid tumors
RG6333	CD19 x CD28 + glofitamab	r/r NHL
RG6344	BRAF inhibitor (3)	solid tumors
RG6392	-	oncology
RG6433	SHP2i	solid tumors
RG6440	TGFβ (SOF10)	solid tumors
RG7440	ipatasertib + rucaparib	mCRPC, solid tumors
	ipatasertib	prostate cancer, pretreated
RG7446	Morpheus platform	solid tumors
RG7601	Venclexta ± azacitidine	r/r MDS
RG7802	cibisatamab ± T	solid tumors
RG7827	FAP-4-1BBL + combos	solid tumors
RG7828	mosunetuzumab monotherapy + combos	heme tumors
CHU	FIXa x FX	haemophilia
CHU	glypican-3 x CD3	solid tumors
CHU	codrituzumab	HCC
CHU	CD137 switch antibody	solid tumors
CHU	LUNA18	solid tumors
CHU	SPYK04	solid tumors
SQZ	PBMC vaccine	solid tumors
RG6287	-	IBD
RG6341	-	asthma
RG6418	selnoflast (NLRP3 inh)	inflammation
RG6315	-	immunologic disorders
RG7828	mosunetuzumab	systemic lupus erythematosus
RG7880	efmarodocokin alfa	aGVHD
RG6006	Abx MCP	bacterial infections
RG6319	LepB inhibitor	complicated urinary tract infection
RG6338	-	metabolic diseases
RG6035	BS-CD20 MAb	multiple sclerosis
RG6091	rugonersen (UBE3A LNA)	Angelman syndrome
RG6163	-	psychiatric disorders
RG6182	-	neurodegenerative diseases
RG6237	latent myostatin	neuromuscular disorders
RG6289	-	Alzheimer´s
RG7637	-	neurodevelopmental disorders
RG6120	VEGF-Ang2 DutaFab	nAMD
RG6312	-	geographic atrophy
RG6501*	OpRegen	geographic atrophy
RG7921	-	nAMD
CHU	AMY109	endometriosis

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases

Metabolism
Neuroscience
Ophthalmology
Other

[1]combination platform
T=Tecentriq, BS=Brain shuttle

RG-No - Roche/Genentech
CHU - Chugai managed
IONIS – IONIS managed
SQZ - SQZ Biotechnology managed
*Lineage Cell Therapeutics managed

Phase II (22 NMEs + 13 AIs)

RG6026	glofitamab + chemo	1L ctDNA high risk DLBCL
RG6058	tiragolumab + T	NSCLC
	tiragolumab + T + chemo	1L non-squamous NSCLC
	tiragolumab + T + chemo	neoadj-adj NSCLC
	tiragolumab + T	cervical cancer
	tiragolumab + T	1L PD-L1+ mSCCHN
RG6107	crovalimab	sickle cell disease
RG6139	PD1 x LAG3	solid tumors
RG6171	giredestrant (SERD)	neoadjuvant ER+ BC
	giredestrant (SERD)	2/3L ER+/HER2- mBC
RG6180	autogene cevumeran + pembrolizumab	1L melanoma
RG6354	zinpentraxin alfa (PRM-151)	myelofibrosis
RG6357	SPK-8011	hemophilia A
RG6358	SPK-8016	hemophilia A with inhibitors to factor VIII
RG7601	Venclexta + carfilzomib	r/r MM t(11;14)
CHU	Oncolytic Type 5 adenovirus	esophageal cancer
RG6149	astegolimab (Anti-ST2)	COPD
RG6173	anti-tryptase	asthma
IONIS	ASO factor B	IgA nephropathy
RG7854/RG7907/RG6346/RG6084[1]	TLR7 ago(3)/CpAM (2)/ siRNA/PDL1 LNA	HBV
RG6359	SPK-3006	Pompe disease
RG6100	semorinemab	Alzheimer's
RG6102	BS-gantenerumab	Alzheimer's
RG6416	bepranemab	Alzheimer's
RG7412	crenezumab	familial Alzheimer's healthy pts
RG7816	alogabat (GABA Aa5 PAM)	ASD
RG7906	ralmitaront	schizophrenia
RG7935	prasinezumab	Parkinson's
RG6147	galegenimab (HtrA1)	geographic atrophy
RG6179	-	DME
RG7774	-	retinal disease
IONIS	ASO factor B	geographic atrophy

Status as of April 25, 2022

Roche Group development pipeline

Phase III (10 NMEs + 40 AIs)

RG3502	Kadcyla + T	2L+ HER-2+ PD-L1+ mBC
	Kadcyla + T	HER-2+ eBC high-risk
RG6026	glofitamab + chemo	2L+ DLBCL
RG6058	tiragolumab + T	1L PD-L1+ NSCLC
	tiragolumab + T	locally advanced esophageal cancer
	tiragolumab + T	1L esophageal cancer
	tiragolumab + T	stage III unresectable 1L NSCLC
RG6107	crovalimab	PNH
	crovalimab	aHUS
RG6114	inavolisib (mPI3K alpha inh)	1L HR+ mBC
RG6171	giredestrant (SERD)	ER+/HER2- mBC
	giredestrant (SERD)	adj ER+ BC
RG6268	Rozlytrek ROS1+	1L NSCLC
RG7440	ipatasertib + abiraterone	1L CRPC
RG7446	Tecentriq + platinum chemo	NSCLC neoadj
	Tecentriq	NMIBC, high risk
	Tecentriq	RCC adj
	Tecentriq + cabozantinib	advanced RCC
	Tecentriq + cabozantinib	2L NSCLC
	T ± chemo	SCCHN adj
	T + capecitabine or carbo/gem	1L TNBC
	T + paclitaxel	TNBC adj
	T + Avastin	HCC adj
	T ± chemo	1L mUC
	Tecentriq	SC NSCLC
	Tecentriq	ctDNA+ high-risk MIBC
	T+ lurbinectedin	1L maintenance SCLC
RG7601	Venclexta	r/r MM t(11:14)
	Venclexta + azacitidine	1L MDS
RG7828	mosunetuzumab + lenalidomide	2L+ FL
RG7853	Alecensa	ALK+ NSCLC adj
RG3648	Xolair	food allergy
RG6354	zinpentraxin alfa (PRM-151)	IPF
RG7159	Gazyva	lupus nephritis
	Gazyva	membranous nephropathy
	Gazyva	systemic lupus erythematosus
RG6152	Xofluza	influenza, pediatric (0-1 year)
	Xofluza	influenza direct transmission
RG1450	gantenerumab	Alzheimer's
RG1594	Ocrevus higher dose	RMS & PPMS
RG6042	tominersen	Huntington's
RG6168	Enspryng	myasthenia gravis
RG6356	delandistrogene moxeparvovec (SRP-9001)	DMD
RG7845	fenebrutinib	RMS
RG7845	fenebrutinib	PPMS
RG6321	Susvimo (PDS)	DME
	Susvimo (PDS)	DR
	Susvimo (PDS)	wAMD, 36-week
RG7716	Vabysmo (faricimab)	BRVO
	Vabysmo (faricimab)	CRVO

T=Tecentriq
PDS=Port Delivery System with ranibizumab

Registration US & EU (4 NMEs + 9 AIs)

RG6013	Hemlibra[1]	mild to moderate hemophilia A
RG6026	glofitamab[1]	3L+ DLBCL
RG6396	Gavreto[2]	RET+ MTC, TC
RG7446	Tecentriq[2]	NSCLC adj
RG7596	Polivy[1]	1L DLBCL
RG7828	mosunetuzumab	3 L+ FL
RG6321	Susvimo (PDS)	wAMD
RG7716	Vabysmo (faricimab)[3]	DME
	Vabysmo (faricimab)[3]	wAMD
RG6152	Xofluza	influenza, pediatric
RG56413+ RG6412	Ronapreve	SARS-CoV-2 hospitalised
RG1569	Actemra[4]	COVID-19 pneumonia
RG7916	Evrysdi	SMA pediatric <2months

[1] Filed in the EU
[2] Approved in US
[3] Approved in US, filed in EU
[4] Approved in EU

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other

Status as of April 25, 2022

NME submissions and their additional indications

Projects in phase II and III

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases

Metabolism
Neuroscience
Ophthalmology
Other

2022

RG6026	**glofitamab** 3L+ DLBCL ✓
RG6058	**tiragolumab + T** 1L PD-L1+ NSCLC
RG6058	**tiragolumab + T** 1L esophageal cancer (CN)
RG6107	**crovalimab** PNH (CN)
RG6171	**giredestrant** (SERD) 2L/3L ER+/HER2- mBC
RG7440	**ipatasertib + abiraterone** 1L CRPC
RG1450	**gantenerumab** Alzheimer's

2023

RG6321	**Susvimo** (PDS) DME
RG6321	**Susvimo** (PDS) DR (US)
RG7716	**Vabysmo** (faricimab) BRVO/CRVO

2024

RG6058	**tiragolumab + T** Stage III unresectable 1L NSCLC
RG6107	**crovalimab** aHUS
RG6114	**inavolisib** (mPI3K alpha inh) 1L HR+ BC
RG6354	**zinpentraxin alfa** (PRM-151) IPF
RG6356	**delandistrogene moxeparvovec** (SRP-9001) DMD

2025 and beyond

RG6026	**glofitamab + chemo** 2L DLBCL
RG6026	**glofitamab + chemo** 1L ctDNA+ high risk DLBCL
RG6058	**tiragolumab + T** 1L PD-L1+ cervical cancer
RG6058	**tiragolumab + T** locally adv esophageal cancer
RG6058	**tiragolumab + T** 1L non-sq NSCLC
RG6058	**tiragolumab + T** 1L PD-L1+ mSCCHN
RG6058	**tiragolumab+T+/- chemo** neoadj/adj NSCLC
RG6107	**crovalimab** sickle cell disease
RG6139	**PD1xLAG3** solid tumors
RG6171	**giredestrant** (SERD) 1L ER+/HER2- mBC
RG6171	**giredestrant** (SERD) Adj ER+ BC
RG6180	**autogene cevumeran** 1L melanoma
RG6354	**zinpentraxin alfa** (PRM-151) myelofibrosis
RG7828	**mosunetuzumab + lenalidomide** 2L FL
RG6149	**astegolimab** (anti-ST2) COPD
RG6173	**anti-tryptase** asthma
RG7907/ RG7854/ RG6346/ RG6084	**TLR7 ago (3)/CpAM (2) /siRNA/ PDL1 LNA** HBV
RG6100	**semorinemab** Alzheimer's
RG6102	**brain shuttle gantenerumab** Alzheimer's
RG6416	**bepranemab** Alzheimer's
RG7816	**alogabat** (GABA Aa5 PAM) ASD
RG7845	**fenebrutinib** RMS
RG7845	**fenebrutinib** PPMS
RG7906	**ralmitaront** schizophrenia
RG7935	**prasinezumab** Parkinson's
RG6321	**Susvimo** (PDS) wAMD, 36-week refill
RG6147	**galegenimab** (HtrA1) geographic atrophy
RG6179	**NME** DME
RG7774	**NME** retinal disease

Status as of April 25, 2022

✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
PDS=Port Delivery System with ranibizumab

AI submissions for existing products

Projects in phase II and III

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other

2022

RG6413+ RG6412	**Ronapreve**** SARS-CoV-2 hospitalized (EU) ✓
RG1569	**Actemra** COVID-19 pneumonia[1] ✓
RG7446	**Tecentriq** RCC adj
RG7446	**Tecentriq ± chemo** 1L mUC
RG7596	**Polivy** 1L DLBCL (US)
RG6268	**Rozlytrek (BFAST)** 1L NSCLC ROS1+

2023

RG3648	**Xolair** food allergy
RG6152	**Xofluza** direct transmission
RG6152	**Xofluza** influenza, pediatric (0-1 year)
RG6396	**Gavreto** Tumour agnostic
RG7446	**Tecentriq** SC NSCLC
RG7446	**Tecentriq + cabozantinib** 2L NSCLC
RG7446	**Tecentriq + cabozantinib** adv RCC
RG7446	**Tecentriq + Avastin** HCC adj
RG7446	**Tecentriq[2]** NSCLC neo adj
RG7601	**Venclexta** r/r MM t(11:14)
RG7446	**Tecentriq + capecitabine or carbo/gem** TNBC
RG7853	**Alecensa** ALK+ NSCLC adj

2024

RG7446	**Tecentriq** ctDNA+ high-risk MIBC
RG7446	**Tecentriq** SCCHN adj
RG7601	**Venclexta + azacitidine** 1L MDS
RG7159	**Gazyva** lupus nephritis
RG6168	**Enspryng** myasthenia gravis

2025 and beyond

RG3502	**Kadcyla + Tecentriq** 2L+ HER-2+ PD-L1+ mBC
RG3502	**Kadcyla + Tecentriq** HER-2+ eBC high-risk
RG7446	**Tecentriq + paclitaxel** TNBC adj
RG7446	**Tecentriq** High risk NMIBC
RG7446	**Tecentriq+ lurbinectedin** 1l maintenance SCLC
RG7159	**Gazyva** membranous nephropathy
RG7159	**Gazyva** systemic lupus erythematosus
RG1594	**Ocrevus** higher dose RMS & PPMS

Status as of April 25, 2022

✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
[1]Approved in EU, filed in US
[2]filing timeline based on data from interim analysis

PDS=Port Delivery System with ranibizumab
**Ronapreve (casirivimab+imdevimab also known as REGEN-COV in the US) developed in collaboration with Regeneron Pharmaceuticals

Major pending approvals 2022

US	
RG6152	**Xofluza** influenza pediatric Filed March 2020
RG7916	**Evrysdi** SMA presymptomatic pediatric <2mo Filed Nov 2021
RG7828	**mosunetuzumab** 3L+ FL Filed Dec 2021
RG1569	**Actemra** COVID-19 pneumonia Filed Jan 2022

EU	
RG6321	**Susvimo (PDS)** wAMD Filed April 2021
RG7716	**Vabysmo (faricimab)** DME Filed May 2021
RG7716	**Vabysmo (faricimab)** wAMD Filed May 2021
RG7446	**Tecentriq** NSCLC adj Filed June 2021
RG6013	**Hemlibra** mild to moderate hemophilia A Filed Oct 2021
RG6396	**Gavreto** RET+ MTC, TC Filed Nov 2021
RG6152	**Xofluza** influenza pediatric Filed Nov 2021
RG7916	**Evrysdi** SMA presymptomatic pediatric <2mo Filed Nov 2021
RG7596	**Polivy** 1L DLBCL Filed Dec 2021
RG7828	**mosunetuzumab** 3L+ FL Filed Dec 2021
RG6413+ RG6412	**Ronapreve**** SARS-CoV-2 hospitalized Filed Jan 2022
RG6026	**glofitamab** 3L+ DLBCL Filed April 2022

China	
RG6268	**Rozlytrek** ROS1+ NSCLC Filed Oct 2021
RG6268	**Rozlytrek** NTRK+ solid tumors Filed Nov 2021
RG7596	**Polivy** 1L DLBCL Filed Nov 2021
RG7596	**Polivy** R/R DLBCL Filed Dec 2021

Japan-Chugai	
RG7446	**Tecentriq** NSCLC adj Filed July 2021
RG6013	**Hemlibra** acquired Haemophilia A Filed Nov 2021
RG7596	**Polivy** 1L DLBCL Filed Dec 2021
RG7159	**Gazyva** 1L CLL Filed March 2022

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other

Status as of April 25, 2022

PDS=Port Delivery System with ranibizumab
**Ronapreve (casirivimab+imdevimab also known as REGEN-COV in the US) developed in collaboration with Regeneron Pharmaceuticals

Major granted approvals 2022

US

RG7716	**Vabysmo (faricimab)** DME Jan 2022
RG7716	**Vabysmo (faricimab)** wAMD Jan 2022
RG1569	**Actemra** GCA IV Feb 2022

EU

China

RG7446	**Tecentriq** NSCLC adj March 2022
RG1569	**Actemra** RA SC April 2022

Japan-Chugai

RG1569	**Actemra** COVID-19 pneumonia Jan 2022
RG7716	**Vabysmo (faricimab)** DME March 2022
RG7716	**Vabysmo (faricimab)** wAMD March 2022
RG1273	**Perjeta + Herceptin** HER-2+ CRC March 2022

- New Molecular Entity (NME)
- Additional Indication (AI)
- Oncology / Hematology
- Immunology
- Infectious Diseases
- Metabolism
- Neuroscience
- Ophthalmology
- Other

Status as of April 25, 2022

Doing now what patients need next